Early innate cell interactions with Mycobacterium tuberculosis in protection and pathology of tuberculosis
infant lung infection :: Article Creator DRL To Distribute Sanofi's Beyfortus, Used To Prevent RSV In Infants Against the backdrop of World Immunization Week, Dr Reddy's Laboratories Ltd and Sanofi Healthcare India have expanded their partnership to bring in Beyfortus – a novel drug to prevent respiratory syncytial virus in infants. Dr Reddy's expects to launch Beyfortus in India in the second quarter of the current fiscal year, it said. Beyfortus contains the monoclonal antibody, nirsevimab, in a prefilled injection used to prevent RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, a joint note from the companies said. It is also administered in children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season, it added. Beyfortus has been approved for use in the European Union, the US, China, Japan, and many other countries ar...